A Study of Tucatinib vs. Placebo in Combination With Trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Condition:   HER2-positive Breast Cancer Interventions:   Drug: tucatinib;   Drug: placebo;   Drug: T-DM1 Sponsor:   Seattle Genetics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials